Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) finished Friday with an addition of $0.01 to close at $0.24, an upside of 4.82 percent. An average of 748,420 shares of common stock have been traded in the last five days. There was a gain of $0.0019 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 4,268,575 shares traded, while the 50-day average volume stands at 3,079,878.
PIRS stock has increased by 17.34% in the last month. The company shares reached their 1-month lowest point of $0.1842 on 07/19/23. With the stock rallying to its 52-week high on 02/02/23, shares of the company touched a low of $0.16 and a high of $1.97 in 52 weeks. It has reached a new high 12 times so far this year and lost -77.22% or -$0.8031 in price. In spite of this, the price is down -87.97% from the 52-week high.
Valuation Metrics
Pieris Pharmaceuticals Inc. (PIRS) stock’s beta is 0.82. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.11, the price-to-book (PB) ratio at 1.13.
Financial Health
The quick ratio of Pieris Pharmaceuticals Inc. for the three months ended March 30 was 1.40, and the current ratio was 1.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Pieris Pharmaceuticals Inc.’s EBITDA margin for the year ending March 30 is -157.11%. Its gross profit as reported stood at $69.38 million compared to revenue of $25.9 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Pieris Pharmaceuticals Inc.’s return on assets was -42.30%.
Earnings Surprise
For the three-month period that ended March 30, Pieris Pharmaceuticals Inc. had $9.94 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $3.98 million in the quarter, while revenues of -$13.18 million were grew 359.8%. The analyst consensus anticipated Pieris Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.14 per share, but it turned out to be -$0.18, a -28.60% surprise. For the quarter, EBITDA amounted to -$14.91 million. Shareholders own equity worth $82.02 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Pieris Pharmaceuticals Inc. (PIRS) price momentum. RSI 9-day as of the close on 11 August was 56.32%, suggesting the stock is Neutral, with historical volatility in this time frame at 47.64%.
As of today, PIRS’s price is $0.2248 +0.81% or $0.0019 from its 5-day moving average. PIRS is currently trading +21.49% higher than its 20-day SMA and -80.42% lower than its 100-day SMA. However, the stock’s current price level is -72.06% below the SMA50 and -76.54% below the SMA200.
The stochastic %K and %D were 57.78% and 50.75%, respectively, and the average true range (ATR) was 0.0222. With the 14-day stochastic at 79.18% and the average true range at 0.0293, the RSI (14) stands at 43.11%. The stock has reached 0.0022 on the 9-day MACD Oscillator while the 14-day reading was at 0.0059.
Analyst Ratings
Robert W. Baird upgraded Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Pieris Pharmaceuticals Inc. (PIRS) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PIRS, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
